Interview with Stephen Turley, Managing Director, Lundbeck Limited (UK)
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
Address: Lundbeck House, Caldecotte Lake Drive, Caldecotte Lake, , Milton Keynes, MK7 8LG, United Kingdom
,United Kingdom
Tel: 0044 1908 649 966
Web: http://uk.lundbeck.com/uk/
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ a total of 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back more than 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from neurological disorders.
Lundbeck UK are specialists in psychiatry and pioneers in neurology. We are an international pharmaceutical organisation with a head office based in Milton Keynes, UK and a national field force. The office consists of; Sales & Marketing, Finance & Administration, Human Resources, Medical, and Business Intelligence.
Specialists in psychiatry, pioneers in neurology
As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmaceuticals for psychiatric and neurological disorders, and are pioneers of new treatments and new approaches.
As specialists, our research and development is focused and concentrated. As specialists, we maintain close ties to our customers, establishing new links, building knowledge and developing new programmes. And as specialists, we are closer to the people suffering from psychiatric disorders and the people treating them.
UK Brand Name UK Generic Name
Azilect 1mg Tablets rasagiline
Circadin 2mg prolonged-release tablets melatonin
Cipralex 5mg/10mg/20mg Tablets escitalopram
Cipralex 10mg/ml Drops escitalopram
Cipramil 40mg/ml Drops citalopram
Cipramil 10mg/20mg/40mg Tablets citalopram
Clopixol Acuphase Injection zuclopenthixol
Clopixol Conc Injection zuclopenthixol
Clopixol Injection zuclopenthixol
Clopixol 2mg/10mg/25mg Tablets zuclopenthixol
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug…
Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how…
Only 14 months in position, UK country president at Novartis, Haseeb Ahmad, shares insights into the company’s new strategy. He further analyses how Brexit can be a catalysing force for…
Recently appointed CEO of Health Innovation Manchester, Ben Bridgewater explains the organization’s goal of improving the lives of the people of Greater Manchester by ensuring a constant pipeline of innovation,…
Taking the conversation beyond Brexit, His Excellency Lars Thuesen, ambassador of Denmark to the UK, highlights the solid ties that have linked both countries since the Danes invaded the island…
The Ambassador of Switzerland to the UK, Alexandre Fasel, discloses what has been achieved so far with the ‘Mind the Gap’ strategy, aimed at safeguarding British-Swiss economic and business…
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Hugo Fry, managing director of Sanofi UK, details the impact of the company’s changing structure, the continued relevance of the UK market despite the challenges around Brexit, and the significance…
With an appetite to take the next step in its rapid development, EUSA Pharma has already established itself as a leading rare-disease and oncology biotech company in just a short…
Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry (ABPI) reveals his staunch faith in the British health service but calls for the NHS to welcome and…
See our Cookie Privacy Policy Here
